Originally published on BioSpace iStock, alexkich As AAV9 and CRISPR programs navigate safety, delivery and scalability hurdles, small molecules offer a […]
Funding to speed development of next‑generation treatments for Duchenne muscular dystrophy. RENO, NV, UNITED STATES, August 22,2025 /EINPresswire.com/ —Sarcomatrix Therapeutics,
Proceeds to support IND preparation and first-in-human studies targeting muscle-wasting diseases RENO, NV, UNITED STATES, April 22, 2025 /EINPresswire.com/ — Sarcomatrix
The renewal highlights ongoing progress in developing rhLAM-111 for rare muscular diseases, with a new emphasis on Duchenne Muscular Dystrophy.
January 23, 2025 / The Clinical Trial Vanguard Executive Interviews In this interview, we engage with David Craig from Sarcomatrix
RENO, NV, UNITED STATES, January 07, 2025 – Sarcomatrix Therapeutics, a biotech innovator in muscle disease therapies, today announced a
RENO, NV, UNITED STATES, January 6, 2025 /EINPresswire.com/ — Reno, NV – January 6, 2025 – Sarcomatrix Therapeutics, a pioneering
RENO, NV, UNITED STATES, January 2, 2025 /EINPresswire.com/ — Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as
RENO, NV, UNITED STATES, September 27, 2024 /EINPresswire.com/ — Sarcomatrix Therapeutics, an emerging leader in the development of innovative therapies
We are thrilled to be selected for the Startup World Cup. It’s a testament to the dedication and hard work
Your investment can help us accelerate pre-clinical research and move on to in-human trials so we can start offering treatments as soon as possible.
